Ilevro

Chronic Pain, Inflammation, Cataract Surgery

Treatment

5 FDA approvals

20 Active Studies for Ilevro

What is Ilevro

Nepafenac

The Generic name of this drug

Treatment Summary

Nepafenac is a medication used to treat pain and inflammation after cataract surgery. It is an NSAID (non-steroidal anti-inflammatory drug) that comes in the form of a prescription eye drop.

Nevanac

is the brand name

image of different drug pills on a surface

Ilevro Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nevanac

Nepafenac

2005

5

Approved as Treatment by the FDA

Nepafenac, also known as Nevanac, is approved by the FDA for 5 uses like Pain and Inflammation .

Pain

Helps manage Pain

Inflammation

Helps manage Inflammation

Chronic Pain

Helps manage Pain

Cataract Surgery

Helps manage Cataract Surgery

Inflammation

Helps manage Inflammation

Effectiveness

How Ilevro Affects Patients

When Nepafenac ophthalmic suspension is taken three times a day, measurable amounts of Nepafenac and Amfenac are present in the blood after two and three hours respectively. On average, the maximum amount of Nepafenac and Amfenac in the blood was 0.310 and 0.422 nanograms per milliliter, respectively.

How Ilevro works in the body

Nepafenac is a drug that is changed in the body to amfenac, a type of pain reliever. Amfenac works by blocking the activity of two enzymes, COX1 and COX2. This helps reduce inflammation and pain.

When to interrupt dosage

The recommended measure of Ilevro is contingent upon the diagnosed condition, for example Inflammation, Cataract Surgery and Chronic Pain. The quantity of dosage fluctuates, according to the administration mode (e.g. Suspension / drops or Ophthalmic) featured in the table beneath.

Condition

Dosage

Administration

Chronic Pain

, 1.0 mg/mL, 3.0 mg/mL, 0.3 %, 0.1 %

Suspension / drops - Ophthalmic, , Ophthalmic, Suspension / drops, Suspension, Suspension - Ophthalmic

Cataract Surgery

, 1.0 mg/mL, 3.0 mg/mL, 0.3 %, 0.1 %

Suspension / drops - Ophthalmic, , Ophthalmic, Suspension / drops, Suspension, Suspension - Ophthalmic

Inflammation

, 1.0 mg/mL, 3.0 mg/mL, 0.3 %, 0.1 %

Suspension / drops - Ophthalmic, , Ophthalmic, Suspension / drops, Suspension, Suspension - Ophthalmic

Warnings

Ilevro Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Ilevro.

Common Ilevro Drug Interactions

Drug Name

Risk Level

Description

Valproic acid

Minor

The protein binding of Valproic acid can be decreased when combined with Nepafenac.

Acemetacin

Moderate

The risk or severity of adverse effects can be increased when Nepafenac is combined with Acemetacin.

Acetylsalicylic acid

Moderate

The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Nepafenac.

Alclofenac

Moderate

The risk or severity of adverse effects can be increased when Nepafenac is combined with Alclofenac.

Alminoprofen

Moderate

The risk or severity of adverse effects can be increased when Nepafenac is combined with Alminoprofen.

Ilevro Toxicity & Overdose Risk

Applying non-steroidal anti-inflammatory drugs to the eyes can lead to increased bleeding in the eye area during eye surgery.

image of a doctor in a lab doing drug, clinical research

Ilevro Novel Uses: Which Conditions Have a Clinical Trial Featuring Ilevro?

357 active studies are currently being undertaken to assess the potential of Ilevro in alleviating Inflammation, Chronic Pain and assisting with Cataract Surgery.

Condition

Clinical Trials

Trial Phases

Inflammation

58 Actively Recruiting

Not Applicable, Early Phase 1, Phase 1, Phase 2, Phase 3, Phase 4

Chronic Pain

130 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1

Cataract Surgery

3 Actively Recruiting

Not Applicable, Phase 4

Ilevro Reviews: What are patients saying about Ilevro?

5

Patient Review

8/28/2016

Ilevro for Inflammation of the Eye Following Surgery

I took this treatment once a day for 7 days, and then due to irritation from the antibiotic, I dropped down to 2 drops a day for 7 days. I had a sample bottle which only lasted me until day 11. From my experience, I think that one bottle would last if you're only taking 1 drop a day for two weeks. However, since I ran out before finishing the full 14 days, I had to get a prescription for the other eye. This medication is pricey, but my insurance did give me a special authorization and covered it.

5

Patient Review

6/17/2017

Ilevro for Inflammation of the Eye Following Surgery

Helped to relieve pain after a failed glaucoma surgery. Not as easy to apply as OTC eyedrops, but this was much more effective and long-lasting.

4

Patient Review

10/29/2013

Ilevro for Inflammation of the Eye Following Surgery

3.3

Patient Review

1/1/2014

Ilevro for Inflammation of the Eye Following Surgery

The bottle was very small and expensive. The design of the bottle tip was such that the medication would drip down the side of the bottle after application, wasting a small amount each time. Other eye drops I used had better tip design.

3

Patient Review

3/22/2019

Ilevro for Inflammation of the Eye Following Surgery

I used this once in the morning and evening for cataracts/LASIK and it did the job well. The only side effect was temporary blurring, but that was manageable. The bottle is really difficult to use though.

2

Patient Review

3/26/2016

Ilevro for Postoperative Pain in Eye

The bottle is rigid, and the fluid inside is very viscous. It barely lasted me three weeks. Since it's not a covered medication, unless you're careful with your usage, you'll end up having to pay for another bottle before you're supposed to.

1.7

Patient Review

8/8/2014

Ilevro for Postoperative Pain in Eye

The design of this dropper is very poor. There is only enough medicine for 25 days, so you have to be careful when using it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ilevro

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug Ilevro used for?

"This medication is used to relieve eye pain, irritation, and redness following cataract eye surgery. Nepafenac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs work by reducing swelling and inflammation."

Answered by AI

What are the side effects of Ilevro eye drops?

"The sensation of a foreign body in the eye, increased intraocular pressure, a sticky sensation in the eye, eye or eyelid swelling, dry eye, crusting of the eyelids, eye discomfort or pain, and itchy eyes are all symptoms of conjunctivitis."

Answered by AI

What kind of drug is Ilevro?

"Ilevro is a non-steroidal anti-inflammatory drug (NSAID) that lessens pain and swelling in the eye due to surgery by stopping your body from making chemicals that cause inflammation."

Answered by AI

Is Ilevro a generic drug?

"At the moment, there is no cheaper alternative to Ilevro that has the same therapeutic effect in the United States. Be aware that there are many illegal online pharmacies that might try to sell you a generic version of Ilevro. These medicines could be fake and potentially dangerous."

Answered by AI

Clinical Trials for Ilevro

Image of UCI Health Susan Samueli Integrative Health Institute in Irvine, United States.

Biofield Therapy for Cancer

18+
All Sexes
Irvine, CA

Cancer treatment with immunotherapy is often associated with symptoms such as fatigue, pain, and emotional distress, which may affect patients' daily functioning and quality of life. Additional supportive care approaches are being studied to better understand their potential role in supporting these symptoms. The purpose of this study is to learn whether a biofield therapy, called Reiki may help to support adults with cancer who are receiving immunotherapy and currently struggling with fatigue. Reiki is a non-invasive complementary therapy delivered by a trained practitioner who places their hands lightly near the body. It is intended to promote relaxation and support general well-being. Reiki is used as a supportive practice and is not considered a medical treatment or replacement for standard care. The secondary goal of this study is to evaluate the feasibility of delivering Reiki in this clinical setting. This includes examining recruitment, retention, adherence to study procedures, and overall participant engagement. Lastly, the third aim is to explore participants' experiences with Reiki through guided interviews. Participants enrolled in this study will first be asked to participate in a one-hour, one-on-one interview about their experiences with cancer treatment, their symptoms, and their thoughts about integrative care practices such as Reiki. After the interview, they will be randomly assigned to one of two groups: Immediate Reiki Group: If participants are assigned to this group, they will receive six weekly, in-person 30-minute Usui Reiki sessions from a Reiki master at the Susan Samueli Integrative Health Institute. Before and after each session, participants will complete questionnaires about fatigue, pain, and stress. At the first and final sessions, a small blood sample will be collected to measure inflammatory biomarkers, and Electroencephalogram (EEG) hyperscanning will be conducted to measure brain activity and connectivity between the participant and the practitioner. Four weeks after the final session, they will complete the questionnaires again, followed by a short satisfaction survey about their experience. Waitlist Group: If they are assigned to the waitlist group, they will first complete a 6-week observation period that includes brief weekly fatigue questionnaires and two in-person 30-minute sessions with EEG measurements at Week 1 and Week 6. This will be followed by a 4-week period with no sessions, after which they will complete questionnaires about fatigue, pain, and psychological distress. Participants will then begin the same six weekly, in-person 30-minute sessions described above. As with the Immediate Group, they will complete questionnaires before and after each session. At the first and final sessions, a small blood sample will be collected and EEG hyperscanning will be conducted. At the end of the study, participants will also complete a short satisfaction survey about their experience. The investigators hypothesize that participants receiving Reiki will report improvements in symptoms and well-being compared to those not yet receiving Reiki, and that the intervention will be feasible to implement and acceptable to participants.

Recruiting
Has No Placebo

UCI Health Susan Samueli Integrative Health Institute (+1 Sites)

Have you considered Ilevro clinical trials?

We made a collection of clinical trials featuring Ilevro, we think they might fit your search criteria.
Go to Trials
Image of University of Oklahoma Health Campus in Oklahoma City, United States.

Disulfiram for Rheumatoid Arthritis

18 - 75
All Sexes
Oklahoma City, OK

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity. Disulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction. This study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo. The primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.

Phase 2
Waitlist Available

University of Oklahoma Health Campus

Beatriz Y Hanaoka, MD, MSc

Image of University of California, Riverside in Riverside, United States.

Acetazolamide for Altitude Sickness

18 - 65
All Sexes
Riverside, CA

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Phase < 1
Waitlist Available

University of California, Riverside

Have you considered Ilevro clinical trials?

We made a collection of clinical trials featuring Ilevro, we think they might fit your search criteria.
Go to Trials
Image of Marquette University in Milwaukee, United States.

Exercise for Pain

35 - 65
All Sexes
Milwaukee, WI

The goal of this clinical trial is to determine how male and female former athletes experience pain and respond to moderate-intensity exercise (strength versus aerobic) compared with both current master's athletes and nonathletes. The main questions this study aims to address are: 1. How do former athletes, master's athletes, and nonathletes experience pain? 2. How do different types of moderate-intensity exercise (strength versus aerobic exercise) influence pain in former athletes, master's athletes, and nonathletes? Participants will complete 3 different testing sessions: 1. Baseline testing including assessments of strength, cardiorespiratory fitness, and pain; 2. Strength exercise: pain assessments will occur before and after moderate-intensity strength training exercise; 3. Aerobic exercise: pain assessments will occur before and after moderate-intensity aerobic exercise. There will be a washout period of approximately one week or greater between each of the three different testing sessions. The order of conditions (strength versus aerobic exercise) will be randomized (crossover randomized trial design).

Recruiting
Has No Placebo

Marquette University

Jacob J Capin, DPT, PhD

Image of Brigham and women's hospital in Boston, United States.

Corticosteroids for Heart Failure

18 - 80
All Sexes
Boston, MA

This pilot study investigates whether giving a short course of intravenous corticosteroids (methylprednisolone) alongside standard medical care can help patients recovering from heart failure-related cardiogenic shock. Heart failure-related cardiogenic shock happens when chronic heart dysfunction causes poor blood circulation and congestion throughout the body. Often, this condition triggers severe inflammation, making it harder for the heart and other organs to recover, even when temporary mechanical heart pumps are used to support blood flow. The study aims to see if reducing this inflammation with corticosteroids is safe and can help patients get better faster. Researchers will enroll 30 adult patients hospitalized with early-stage (SCAI Stage B or C) cardiogenic shock related to heart failure. To participate, patients must also show high levels of inflammation in their blood, specifically a high-sensitivity C-reactive protein (hsCRP) level of 20 mg/L or higher Participants will be randomly assigned by chance to one of two groups. One group will receive the standard of care alone. The other group will receive the standard of care plus a 7-day course of intravenous methylprednisolone. The main goal of the study is to measure the change in inflammation levels (hsCRP) over 7 days. Researchers will also monitor how well the patients' organs recover, track their need for blood pressure medications or mechanical heart pumps, and monitor for any side effects to ensure the treatment is safe

Phase 2
Waitlist Available

Brigham and women's hospital

Image of Donald Berman Maimonides Maimonides Geriatric Centre in Montreal, Canada.

Virtual Reality for Pain

Any Age
All Sexes
Montreal, Canada

This study will test whether immersive virtual reality (iVR) can reduce pain and discomfort during wound care for residents living in long-term care (LTC). Pressure ulcers are common and painful among older adults, and dressing changes often cause additional distress. Up to 20 residents at the Donald Berman Maimonides Geriatric Centre will use virtual reality headsets during routine wound care. The headsets display calm, low-stimulus scenes (e.g., puppies in a meadow) designed to distract and comfort participants. Each participant will take part for six weeks in three phases: * Two weeks of usual wound care (baseline) * Two weeks using virtual reality during wound care (intervention) * Two weeks of usual care again (washout) Pain will be assessed using validated tools, and the research team will also observe agitation, mood, and other behavioral indicators. Nursing staff will provide feedback on feasibility and acceptability of iVR use in LTC settings.

Recruiting
Has No Placebo

Donald Berman Maimonides Maimonides Geriatric Centre

Machelle Wilchesky, PhD

Have you considered Ilevro clinical trials?

We made a collection of clinical trials featuring Ilevro, we think they might fit your search criteria.
Go to Trials